Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $197 | $60 | $4 | $0 |
| % Growth | 229.7% | 1,517.1% | – | – |
| Cost of Goods Sold | $19 | $5 | $1 | $1 |
| Gross Profit | $177 | $55 | $3 | -$1 |
| % Margin | 90.3% | 91.6% | 79.5% | – |
| R&D Expenses | $76 | $111 | $182 | $146 |
| G&A Expenses | $222 | $0 | $122 | $61 |
| SG&A Expenses | $229 | $185 | $122 | $61 |
| Sales & Mktg Exp. | $7 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $306 | $296 | $305 | $207 |
| Operating Income | -$128 | -$241 | -$302 | -$207 |
| % Margin | -65.3% | -404.5% | -8,183% | – |
| Other Income/Exp. Net | -$11 | -$18 | -$10 | $0 |
| Pre-Tax Income | -$139 | -$259 | -$311 | -$206 |
| Tax Expense | $1 | $3 | $0 | $0 |
| Net Income | -$140 | -$262 | -$311 | -$206 |
| % Margin | -71.3% | -439.8% | -8,449.8% | – |
| EPS | -1.16 | -3.78 | -5.66 | -4.17 |
| % Growth | 69.3% | 33.2% | -35.7% | – |
| EPS Diluted | -1.16 | -3.78 | -5.66 | -4.17 |
| Weighted Avg Shares Out | 121 | 69 | 55 | 49 |
| Weighted Avg Shares Out Dil | 121 | 69 | 55 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $27 | $30 | $16 | $0 |
| Depreciation & Amortization | $3 | $2 | $1 | $1 |
| EBITDA | -$110 | -$227 | -$295 | -$206 |
| % Margin | -55.8% | -381.6% | -7,991.1% | – |